SLC2A1

Across TCGA pan-cancer cohorts, SLC2A1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC2A1 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SLC2A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC2A1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

THYM, LUSC, and LGG are the cancer types where SLC2A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUSC	DFS	Median	All	0.210	0.759	<.001	18	view →
LGG	OS	Median	All	0.295	0.799	.007	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
STAD	DFS	Median	All	1.000	0.648	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC2A1–THYM (OS)

Open the THYM breakdown →